Published in Drug Week, December 17th, 2004
CancerVax plans to use the proceeds from subsequent offerings to continue the clinical development of its lead specific active immunotherapeutic (SAI) product candidate, Canvaxin, to initiate clinical trials of SAI-EGF, its lead SAI product candidate that targets the EGFR signaling pathway, to further the preclinical development of its other product candidates, including its anti-angiogenic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.